| Identification | Back Directory | [Name]
Dehydrovomifoliol | [CAS]
39763-33-2 | [Synonyms]
2-Cyclohexen-1-one, 4-hydroxy-3,5,5-trimethyl-4-[(1E)-3-oxo-1-buten-1-yl]-, (4S)- | [Molecular Formula]
C13H18O3 | [MOL File]
39763-33-2.mol | [Molecular Weight]
222.28 |
| Hazard Information | Back Directory | [Uses]
Dehydrovomifoliol is a AKT/mTOR dual inhibitor. Dehydrovomifoliol reduces lipid accumulation and lipogenesis by inhibiting the AKT/mTOR signaling pathway. Dehydrovomifoliol is used in nonalcoholic fatty liver disease research (NAFLD) . | [Definition]
ChEBI: (6S)-dehydrovomifoliol is a dehydrovomifoliol that has S-configuration at the chiral centre. It has a role as a plant metabolite. It is an enantiomer of a (6R)-dehydrovomifoliol. | [References]
[1] Ma
J, et al. Dehydrovomifoliol Alleviates Nonalcoholic Fatty
Liver Disease via the E2F1/AKT/mTOR Axis: Pharmacophore Modeling and Molecular
Docking Study. Evid Based Complement Alternat Med. 2023 Feb 1;2023:9107598. DOI:10.1155/2023/9107598 |
|
| Company Name: |
BioBioPha Co., Ltd.
|
| Tel: |
0871-65217109 13211707573; |
| Website: |
http://www.biobiopha.com |
| Company Name: |
cjbscvictory
|
| Tel: |
13348960310 |
| Website: |
https://www.weikeqi-biotech.com/ |
|